Premature senescence and cardiovascular disease following cancer treatments: mechanistic insights
Ashita Jain(The University of Texas MD Anderson Cancer Center), Nhat-Tu Le(Houston Methodist), Cielito C. Reyes‐Gibby(The University of Texas MD Anderson Cancer Center), Jake J. Wen(The University of Texas MD Anderson Cancer Center), Sunil Krishnan(Smith Family), Anita Deswal(The University of Texas MD Anderson Cancer Center), Nicolas L. Palaskas(The University of Texas MD Anderson Cancer Center), Xiaolei Xu(Beihua University), Elizabeth A. Olmsted‐Davis(William & Mary), John P. Cooke(Houston Methodist), Khanh Chau(Houston Methodist), Eduardo N. Chini(Mayo Clinic in Arizona), Dale J. Hamilton(Cornell University), Jun‐ichi Abe(The University of Texas MD Anderson Cancer Center), Philip L. Lorenzi(City Of Hope National Medical Center), Alejandra Valdivia Padilla(The University of Texas MD Anderson Cancer Center), Venkata Subrahman K Samanthapudi(The University of Texas MD Anderson Cancer Center), Diego Casanova(The University of Texas MD Anderson Cancer Center), Efstratios Koutroumpakis(The University of Texas MD Anderson Cancer Center), Steven H. Lin(The University of Texas MD Anderson Cancer Center), Sai‐Ching J. Yeung(The University of Texas MD Anderson Cancer Center), Sivareddy Kotla(University of Tennessee Health Science Center), Angelica Paniagua Bojorges(The University of Texas MD Anderson Cancer Center), Guangyu Wang(Tongji University), Selina L. Hernandez Gonzalez(The University of Texas MD Anderson Cancer Center), Joerg Herrmann(Mayo Clinic), Kyung Ae Ko(The University of Texas MD Anderson Cancer Center), Brain Hobbs(The University of Texas at Austin), Minh Thi Nguyen(Houston Methodist), Shaefali P. Rodgers(Houston Methodist), Syed Wamique Yusuf(The University of Texas MD Anderson Cancer Center), Momoko Yoshimoto(The University of Texas Health Science Center at Houston)
Cited by 9
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589